7-Amino-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid;2,2,2-trifluoroacetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 7-Amino-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid;2,2,2-trifluoroacetic acid
• 英文别名: 7-amino-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylic acid;2,2,2-trifluoroacetic acid
• 化学式: C10H15F3N2O5
• 分子量: 300.23
• InChiKey: HUJCANRBEFQZFY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.49
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  113
• 氢给体数：
  3
• 氢受体数：
  9

文献信息

• [EN] 5-HT3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR 5-HT3
  申请人：ENVOY THERAPEUTICS INC

  公开号：WO2014014951A1

  公开（公告）日：2014-01-23

  The present invention provides 5-HT3 receptor antagonists of Formula (I): which are useful for the treatment of diseases treatable by inhibition of 5-HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供了式(I)的5-HT3受体拮抗剂，用于治疗通过抑制5-HT3受体可治疗的疾病，如呕吐、疼痛、药物成瘾、神经退行性和精神障碍以及胃肠道疾病。还提供了含有这类化合物的药物组合物和制备这类化合物的方法。
• METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
  申请人：Catabasis Pharmaceuticals, Inc.

  公开号：EP2854787A2

  公开（公告）日：2015-04-08
• 5-HT3 RECEPTOR ANTAGONISTS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2875011A1

  公开（公告）日：2015-05-27
• [EN] METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)<br/>[FR] MÉTHODES DE DIMINUTION DE LA PROPROTÉINE CONVERTASE SUBTILISINE/KEXINE DE TYPE 9 (PCSK9)
  申请人：CATABASIS PHARMACEUTICALS INC

  公开号：WO2013177536A2

  公开（公告）日：2013-11-28

  The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.